4-(2-(Pyrrolidin-1-yl)ethoxy)aniline → HCID 67481428, compound
Reaction equation
Cl[C:2]1[N:23]=[C:5]2[C:6]([NH:10][C:11]3[C:12]([N:17]([CH3:22])[S:18]([CH3:21])(=[O:20])=[O:19])=[N:13][CH:14]=[CH:15][CH:16]=3)=[CH:7][CH:8]=[CH:9][N:4]2[N:3]=1.[N:24]1([CH2:29][CH2:30][O:31][C:32]2[CH:37]=[CH:36][C:35]([NH2:38])=[CH:34][CH:33]=2)[CH2:28][CH2:27][CH2:26][CH2:25]1.C1(P(C2CCCCC2)C2C=CC=CC=2C2C=CC=CC=2P(C2CCCCC2)C2CCCCC2)CCCCC1>>[CH3:22][N:17]([C:12]1[C:11]([NH:10][C:6]2[C:5]3[N:4]([N:3]=[C:2]([NH:38][C:35]4[CH:36]=[CH:37][C:32]([O:31][CH2:30][CH2:29][N:24]5[CH2:28][CH2:27][CH2:26][CH2:25]5)=[CH:33][CH:34]=4)[N:23]=3)[CH:9]=[CH:8][CH:7]=2)=[CH:16][CH:15]=[CH:14][N:13]=1)[S:18]([CH3:21])(=[O:20])=[O:19]Participants
Procedure
N-Methyl-N-(3-{2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-[1,2,4]triazolo[1,5-a]pyridin-8-ylamino}-pyridin-2-yl)-methanesulfonamide was prepared from N-[3-(2-chloro-[1,2,4]triazolo[1,5-a]pyridin-8-ylamino)-pyridin-2-yl]-N-methyl-methanesulfonamide (75.0 mg, 0.212 mmol) and 4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine (53.0 mg, 0.257 mmol) (prepared as described in J. Med. Chem., 2006, 49, 4451-4454) with 2,2′-bis-dicyclohexylphosphanyl-biphenyl (25.0 mg, 0.0457 mmol) as the ligand in a manner analogous to Example 2d. Product isolated as a brown foam (0.023 g, 21%). 1H NMR (400 MHz, CDCl3, δ, ppm): 8.09 (dd, J=4.6, 1.5 Hz, 1H), 8.05 (d, J=6.5 Hz, 1H), 7.78 (dd, J=8.1, 1.4 Hz, 1H), 7.55 (s, 1H), 7.50 (d, J=9.0 Hz, 2H), 7.28-7.23 (m, 1H), 7.13 (d, J=7.7 Hz, 1H), 6.93 (d, J=9.0 Hz, 2H), 6.74 (t, J=7.2 Hz, 1H), 6.69 (s, 1H), 4.11 (t, J=6.1 Hz, 2H), 3.33 (s, 3H), 3.10 (s, 3H), 2.09 (t, J=6.0 Hz, 2H), 2.67-2.57 (m, 4H), 1.87-1.77 (m, 4H). MS=523 (MH)+.
Sources & evidence
- ORD record
- ord-e0f5a875b9034a64ab27a3fada4a51b1
- Source dataset
- uspto-grants-2014_01
- Patent number
- US08633173B2
Reaction notes
Loading…